DiTEBA Launches New Laboratory Research & Testing Group on LinkedIn
DiTEBA has created a new LinkedIn Laboratory Research & Testing Group. This group's aspiration is to create an environment that encourages discussion on developing new, R&D intensive analytical and bioanalytical approaches that will help expedite the process of bringing new products to market. The Laboratory Research and Testing Group openly welcomes ideas, insights and comments that will help members develop better methodologies and improve the probability of bringing your new products to market.
The pharmaceutical industry is facing a crisis. Looming patent expirations, industry consolidation, increased regulatory agency scrutiny and the worst economic recession and credit crisis in many generations have combined to stall new drug development. The industry is also migrating away from blockbuster drugs that target larger populations toward tailored drugs that target smaller segments of the population.
This has caused companies to avoid new laboratory testing methodologies, preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals.
Furthermore, academic research-based modifications to established laboratory testing procedures in drug development are severely restricted because of the concern over triggering costly adjustments to the established regulatory framework.
A more flexible and R&D intensive approach is clearly needed by both emerging and established pharmaceutical companies, which also takes into account recent advancements in genetic research.
For more information about DiTEBA or about the Laboratory Research and Testing Group on LinkedIn, please contact Sam Ricchezza, Senior Vice President, Business Development at email@example.com.